A Phase II Evaluation Of 9-Nitro-Camptothecin In The Third-Line Treatment Of Recurrent Ovarian Or Primary Peritoneal Cancer
- Determine the antitumor activity of nitrocamptothecin in patients with recurrent or
metastatic ovarian epithelial or primary peritoneal cancer.
- Determine the nature and degree of toxicity of this regimen in these patients.
OUTLINE: Patients receive oral nitrocamptothecin on days 1-5. Treatment continues every 7
days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 2 weeks, then every 3 months for 2 years, and then every 6 months
for 3 years.
PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 22
Primary Purpose: Treatment
Edward C. Grendys, MD
Robert H. Lurie Cancer Center
United States: Federal Government